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DCA 10FFF and reduced treatment times when compared to 
FF. Further study on the role of tumor location is 
recommended to establish more conclusive results. A concern 
with the use of VMAT with SBRT is whether the motion of the 
tumor leads to significant dosing discrepancies. DCA remains 
immune to the MLC interplay effect. 
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Purpose or Objective: To modify helical irradiation of the 
total skin (HITS) technique as the completed-HITS (CHITS) 
with face covering and the bone marrow dose declined 
according to the relapse pattern and hematologic toxicities 
of cutaneous lymphoma patient. 
 
Material and Methods: A 36-year-old woman was diagnosed 
as therapy-refractory cutaneous CD4+ T-cell lymphoma, 
T3N0M0B0, stage IIB. HITS with face sparing using 30 Gy in 40 
fractions, 4 times per week was prescribed in March, 2012. 
The adverse effects included leukopenia. One year later, the 
new patches were noted in right eyebrow and lower eyelid 
which was spared. According to the relapse pattern and 
hematologic toxicities, HITS was revised to improve the plan 
results as CHITS. First, the clinical target volume (CTV) was 
increasing the face targeting to be really whole skin 
irradiated. Second, the planning target volume (PTV) were 
separated into head, chest, abdomen and pelvis with upper 
thigh to maintaining the appropriate PTV coverage and the 
margin for PTV was reduced from 5.0 mm to 3.0 mm 
according to the previous daily image-guided data. Third, the 
central cord complete block (CCCB) was designed from head 
to thigh but not from head to abdomen only. The CCCB 
distance away from PTV was changed from 2.5 cm to 2.2 cm 
to reduce the internal organs and bone marrow dose. 
Additionally, the iliac bone, cervical, thoracic, lumbar spine, 
femoral head and pelvic bone were contoured to be 
references to limit the marrow dose. The uniformity index 
(UI), conformity index (CI), dose of organs at risk were used 
to evaluate the plans. For reducing the toxicity of normal 
organs, we also performed low-dose CHITS of 12 Gy in 12 
fractions. 
 
Results: The UI for head, chest, abdomen and pelvis of CHITS 
were 1.16, 1.12, 1.08 and 1.15 that were similar to HITS of 
1.12, 1.12, 1.08 and 1.12, respectively. For the low-dose 
CHITS, the UI is also similar to CHITS. The conformity of 
CHITS was similar to HITS (1.40 versus 1.37). The mean dose 
of heart, whole lung, right parotid gland, left parotid gland, 
liver, right kidney, left kidney, intestine, bladder, rectum, 
uterus with ovary, and cervix with vagina were reduced in 
15.1% to 45.0%. The mean dose of cervical spine, thoracic 
spine, lumbar spine, right iliac bone, left iliac bone, sacrum, 
right lower pelvic bone, left lower pelvic bone, right femur, 
left femur were reduced in 21.6% to 63.8%. For the low-dose 
CHITS, the normal organ dose were reduced in 47% to 88% 
due to low dose treatment. 
 
Conclusion: The modifications of adding face skin irradiation, 
reduced PTV margin, the distance away from PTV from CCCB 
and virtual structure constraints enabled the CHITS technique 
reduced doses of normal organs and bone marrow 
successfully with keep of uniformity and conformity as HITS 
technique. The low-dose CHITS had the similar results in 
target uniformity and conformity and much lower normal 
organ dose compared to HITS technique. 
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Purpose or Objective: The theoretical benefit of dose 
escalation in NSCLC has been shown by Fenwick whilst others 
have demonstrated a clinical dose response relationship 
(Partridge, Rengan). Additionally, inhomogeneous dose 
distributions have been suggested as a method for increasing 
the absolute dose to the target within normal tissue 
constraints (Warren). The aim of this planning study was to 
combine these concepts and explore the potential tumour 
control probability (TCP) benefit that an inhomogeneous plan 
targeting dose escalation to the iGTV could deliver whilst 
respecting normal tissue tolerances. 
 
Material and Methods: Between January 2014 and April 2015 
20 patients with non-small cell lung cancer (NSCLC) 
underwent 4D-planning CT with motion tracking via the RPM 
system (Varian Medical Systems, Palo Alto, California) for 
definitive (chemo)radiation therapy at our institution. The 
4DCT scan was binned into 10 phases and the MIP and AVIP 
datasets were generated. The iGTVsum was the sum of three 
datasets (0%, 50% and MIP). An iGTV to iCTV margin of 6mm 
(scc) or 8mm (adenocarcinoma) was used with a further 5mm 
to the PTV. OARS were contoured on the AVIP CT set, 
including: combined lung; spinal cord; oesophagus and heart. 
Mean iGTVsum volume of 94.51cm3 (range: 12.44 – 
608.69cm3) and mean PTV volume of 315.51cm3 (range: 
97.02 – 1279.64cm3). Six plans were created: homogeneous 
plans treating the entire PTV to 60Gy in 20 fractions using 
both 3DCRT and RapidArc; and four inhomogeneous RapidArc 
plans developed to deliver 65-80Gy in 5Gy escalated 
increments to iGTVsum (median) and 60Gy to PTV, all in 20 
fractions. 
 
Results: There is a significant (p < 0.05) difference in TCP for 
all escalated plans, ranging from 79.8% for the 65Gy boost to 
94.9% for the 80Gy boost, in comparison to 63.1% for the 
homogeneous RapidArc plan. There is a significant difference 
between the MLD for the various escalated plans (Table 1); 
however, this difference is not clinically significant given 
that tolerance for MLD is in the 17-20Gy region. Similarly, the 
predicted NTCP for the lung for the dose escalated plans 
ranged from 6.2-7.1%. In terms of the V20Gy the only 
significant difference was between the 3D plan and all the 
RapidArc plans (Table 1).  
 
 
The only significant mean oesophageal difference was 
between the 3D plan (20.6Gy) and all the escalated plans 
(17.7-18Gy); however, dose to 1cc of the oesophagus was 
significantly higher for the 80Gy and 3D plans. All spinal cord 
and heart doses were below tolerance for the escalated 
plans. 
